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Case 3: A 63-year-old man with initial AST 68
IU/L and ALT 28 IU/L, alive on day 90.
Globally, aminotransferase levels were only slightly
elevated, with mean initial ALT and AST levels of 49
6 54 IU/L and 112 6 105 IU/L; this is a point worth
noting because previous authors have observed higher
ALT levels in patients with HEV infection. Finally,
HEV seroprevalence was 33%, with no significant
association with demographic or clinical characteristics,
including outcome, as shown in Table 1.
All in all, these data indicate that unsuspected acute
HEV infection is not a common occurrence in American
and European patients with acute or acute-on-chronic
liver failure. However, HEV seroprevalence is high, indi-
cating frequent infection, although asymptomatic in most
cases. Fortuitous detection of HEV is therefore likely to
occur during an episode of ALF or acute-on-chronic liver
failure mainly due to another cause, especially in regions
with a high seroprevalence such as southwestern France.
HEV testing should be performed more systematically,
especially in patients with high ALT levels; and further
studies including larger numbers of HEV cases will have
to be performed in order to determine the real impact of
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REPLY:
The report of Renou et al. adds to our growing
understanding of the complex epidemiology of hepa-
titis E virus (HEV) infection among individuals
residing in industrialized countries. HEV is a single-
stranded RNA virus that can be spread through con-
taminated drinking water, blood products, and as a
zoonosis from infected animals. Acute HEV geno-
type 1 or 2 infection is a leading cause of acute hepa-
titis and jaundice worldwide as well as acute liver
failure (ALF) in endemic countries, particularly in
pregnant women. In addition, acute HEV has been
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implicated in 20%-60% of hospitalized patients pre-
senting with acute-on-chronic liver failure (ACLF)
in some developing countries.(1) Sporadic acute
HEV genotype 3 infection presumably transmitted
from contaminated food or dairy products also
accounts for some cases of icteric hepatitis in
selected regions of Europe, such as Wales, South-
west France, and Denmark, but is exceedingly rare
in most Western countries.(2) In support of this,
only 3 of the 681 (0.4%) adult Americans with ALF
from our multicenter, prospective study were HEV
antibody (anti-HEV) immunoglobulin (Ig) M posi-
tive over a 13-year time span, and none of our cases
were pregnant nor had detectable HEV RNA.(3)
Other studies in the United States have also failed to
implicate HEV as a significant cause of acute or
chronic hepatitis in human immunodeficiency virus-
positive or solid organ transplant patients. Last, the
seroprevalence of detectable anti-HEV IgG is
declining in the United States and other Western
countries for unclear reasons.
Renou et al. now report that only 3 of 181 (1.6%)
hospitalized patients with decompensated alcoholic
liver disease enrolled in a multicenter French cohort
study had a weakly positive anti-HEV IgM, and all
of them were HEV RNA negative. In addition,
anti-HEV IgG seropositivity (34%) was not associ-
ated with the severity of liver disease or clinical out-
comes. The findings of Renou et al. are in keeping
with a recent report from the HALT-C study group
that also failed to implicate unsuspected acute HEV
infection as a cause of decompensation in patients
with advanced hepatitis C virus fibrosis.(4) Further-
more, investigators from Paris, France, recently
reported that only 3 of their 84 (3.5%) hospitalized
patients with severe alcoholic hepatitis had evidence
of acute HEV infection, but 2 of the 3 anti-HEV
IgM-positive patients had detectable HEV geno-
type 3 by polymerase chain reaction.(5) The differ-
ence in results across studies could, in part, relate to
the variable sensitivity and specificity of the sero-
logical assays used. The Beijing Wantai test is
believed to have the best performance characteris-
tics among the available assays, but additional vali-
dation studies using a World Health Organization
reference sample and carefully constructed test pan-
els are needed.
We congratulate Renou et al. on their important
work regarding the potential role of unsuspected HEV
infection in hospitalized patients with decompensated
alcoholic liver disease. However, additional studies from
well-characterized cohorts of Western patients with
ACLF are still needed to improve our understanding of
the potential routes of transmission, pathogenesis, and
clinical outcomes of previously unsuspected autochtho-
nous HEV infection.
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